Real-world data backs Pluvicto's survival benefit in advanced prostate cancer

Real-world results for Pluvicto hold up outside the clinical trial setting. The French PSMA-REACH study — a retrospective, multicenter chart review across 26 sites — evaluated lutetium Lu 177 vipivotide tetraxetan in 439 heavily pretreated mCRPC patients treated through France's early-access program. The findings, presented at the 2026 ESMO Congress, closely mirror those from the pivotal phase 3 VISION trial that led to the drug's FDA approval in March 2022.

Patients in this cohort had received a median of 3 prior treatments, including at least one ARPI and one taxane chemotherapy. Despite this heavy pretreatment burden, the therapy demonstrated meaningful efficacy with a manageable safety profile — no new safety signals emerged, and 90.4% of adverse events resolved by study's end.

By the Numbers:

• Median overall survival: 13.1 months
• OS rates at 6, 12, and 18 months: 77.9%, 55.6%, and 39.4%
• Median imaging-based PFS: 5.2 months
• Median treatment cycles received: 4 (39.6% completed all 6)
• Adverse events leading to discontinuation: 6.1% of patients

Why it matters: Real-world studies are the true test of whether clinical trial results translate to everyday practice. PSMA-REACH confirms that Pluvicto delivers consistent survival benefits even in a broader, more diverse patient population — strengthening confidence in its use as a standard-of-care option for advanced prostate cancer.